I don't believe the company desires to go it alone on PCa, they are interested in the bigger ccr5/cancer fish. So I seriously doubt negotiations will ultimately fail there.
From the 10Q posted this week below: Currently on the table: License PCa or sell the intellectual property assets. License HIV region specific.
HIV is probably harder to agree upon because the mono indication is unknown, they may be simply waiting for mono pivotal approval to continue discussions, or if really pressed for cash, they could strike a deal with some lucky company to say license HIV for Japan without the full mono evaluation. Seems they have more than one interested party there, but the PCa language.. 'evaluating opportunities' vs the HIV language 'exploratory discussions', leads be to believe the PCa deal is closer.
Licensing Opportunities
We are currently evaluating strategic opportunities with respect to the assets acquired in our November 2018 acquisition of ProstaGene, LLC (“ProstaGene”), including potential licensing or other opportunities to monetize intellectual property assets relating to prostate cancer diagnostics. As an integral part of the acquisition of ProstaGene, we acquired a proprietary technology that demonstrated in a retrospective clinical trial assessing patients for more than 10 years that its prostate cancer prognostic test (“PCa Test”) provides substantial additive discriminative value for predicting outcomes of patients diagnosed with prostate cancer compared to the intermediate Gleason score, the current standard for prostate cancer diagnosis. The clinical objective is to more precisely guide therapeutic options for men thereby avoiding unnecessary surgery (prostatectomy) and radiation and/or chemotherapy with its attendant side effects.
In addition, we continue to conduct exploratory discussions with third parties who have expressed an interest in a licensing arrangement for leronlimab for HIV indications; such proposed arrangements are country or region specific.
Market Data 
Markets 
